# Regional Oncology Research Center

> **NIH NIH P30** · JOHNS HOPKINS UNIVERSITY · 2022 · $7,776,239

## Abstract

ABSTRACT
 The Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins is dedicated to cancer
research, education and training, and patient care, with the overarching goal of creating and applying new
knowledge to improve prevention, screening, detection, diagnosis and treatment of cancer in Maryland (the
SKCCC catchment area) and throughout the nation and the world. This application seeks continued Cancer
Center Support Grant (CCSG) funding for SKCCC Research Programs and Shared Resources (SRs). Since
the previous CCSG renewal in 2016, the SKCCC has eliminated three Research Programs and created one
new Program. Now, the 285 Members, from 34 academic departments throughout Johns Hopkins University,
populate seven Research Programs: the new Cancer Invasion and Metastasis Program, and the established
Programs in Cancer Genetics and Epigenetics, Cancer Immunology, Cancer Molecular and Functional
Imaging, Cancer Chemical and Structural Biology, Hematologic Malignancies and Bone Marrow
Transplantation, and Cancer Prevention and Control. Twelve SRs provide state-of-the-art-or-better support for
SKCCC research and researchers. SKCCC science encompasses discovery research into the molecular
genetics and epigenetics of human tumorigenesis, clinical trials of new immunotherapies and other cancer
treatments, and epidemiologic analyses of lifestyle influences on cancer mortality. Over the past funding
period, SKCCC Members were exceptionally productive, authoring 3,775 publications (23% Intra-
Programmatic, 22% Inter-Programmatic and 66% featuring external collaborators). SKCCC researchers
garnered $78.5 million in current peer-reviewed grant support, including $44.9 million from the National Cancer
Institute. The SKCCC continued to deliver its science to the bedside. From an average 6,374 new cancer
patients treated per year from 2016–2020, an average of 1,647 new subjects were enrolled annually to
interventional studies (26% of newly registered cancer patients); therapeutic studies accrued some 17% of
cancer patients. In addition, the SKCCC has worked successfully to promote inclusion of minority and
underserved patients with cancer in clinical research, yielding a slight increase in minority participation in
interventional trials (22.3% in 2015 to 25.4% in 2020), while African American accrual to interventional trials
remained steady (15.0% in 2015 and 15.6% in 2020). Moving forward, the SKCCC plans: (1) to promote new
breakthroughs in fundamental cancer research that create paradigm-shifting insights into the nature of human
cancers, (2) to translate this pipeline of discovery into practice-changing advances, (3) to overcome barriers
responsible for disparities in cancer outcomes by enhancing the delivery of innovative cancer services
throughout the state of Maryland catchment area, and (4) to integrate research training and career
development of biomedical scientists and health care professionals into all cancer research endeavors.

## Key facts

- **NIH application ID:** 10409343
- **Project number:** 2P30CA006973-59
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** WILLIAM George NELSON
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $7,776,239
- **Award type:** 2
- **Project period:** 1997-05-07 → 2027-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10409343

## Citation

> US National Institutes of Health, RePORTER application 10409343, Regional Oncology Research Center (2P30CA006973-59). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10409343. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*